Evidence that clozapine directly interacts on the GABAB receptor

@article{Wu2011EvidenceTC,
  title={Evidence that clozapine directly interacts on the GABAB receptor},
  author={Ying Wu and Monica Blichowski and Zafiris J. Daskalakis and Z. Wu and Chun Che Liu and Miguel A. Cortez and O. Carter Snead},
  journal={NeuroReport},
  year={2011},
  volume={22},
  pages={637–641}
}
Neurophysiological studies suggest that clozapine may facilitate &ggr;-aminobutyric acid (GABAergic) neurotransmission. Therefore, we studied the interaction between clozapine and the GABAB receptor (GABABR). We showed that clozapine, and not N-desmethylclozapine, which is a metabolite of clozapine, increased the binding of the GABABR antagonist, [3H]-CGP54626A, at GABABRs. Linear regression analysis showed that the correlation between the dose of clozapine and the increase of [3H]-CGP54626A… 

Binding of clozapine to the GABAB receptor: clinical and structural insights

Analysis of the X-ray crystal structure of GABAB receptor along with molecular docking calculations suggests that clozapine could directly bind to the GABAB receptors similar to that of baclofen, which could lead to a better understanding of the pharmacological uniqueness of clozAPine.

Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia

Activation of GABAB receptors inhibits protein kinase B /Glycogen Synthase Kinase 3 signaling

Activation of GABAB receptors significantly inhibits Akt/GSK-3 signaling in a β-arrestin-dependent pathway and may help to identify potentially novel targets through which GABAB receptor agents may exert therapeutic effects in the treatment of schizophrenia.

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

The neurobiological pathophysiology of TRS, particularly the dopaminergic, glutamatergic, and GABAergic pathways are reviewed, and the therapeutic potential of neuromodulation, including electroconvulsive therapy, repetitive transcranials magnetic stimulation, transcranial direct current stimulation, and deep brain stimulation is focused on.

Gamma‐aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment‐resistant schizophrenia: A proton magnetic resonance spectroscopy (1H‐MRS) study

No studies have investigated the relationship between brain GABA levels, as measured by proton magnetic resonance spectroscopy (1H‐MRS), and clozapine response in patients with TRS.

Regulation of macrophage immune responses by antipsychotic drugs

Results indicated that risperidone and clozapine could inhibit Th1 differentiation not only by increasing INF-γ production of PBMC but by inhibiting the release of Th1- inducing cytokines and increasing Th2-inducing cytokines of LPS-stimulated macrophages to modulate and regulate immune responses.

Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management

Since most cases of somnolence were mild to moderate, allowing tolerance to develop over at least 4 weeks is reasonable before discontinuing an antipsychotic, and starting at a lower dose with a slower titration based on psychiatric diagnoses, adjusting doses when necessary, and minimizing concurrent somnlence-prone agents.

Inhibition of the cortex using transcranial magnetic stimulation in psychiatric populations: current and future directions.

Evidence that suggests cortical inhibition deficits among psychiatric populations is reviewed and how each disorder has a specific neurophysiological response to treatment is demonstrated is demonstrated, demonstrating the potential to identify biological markers of neuropsychiatric disorders.

References

SHOWING 1-10 OF 22 REFERENCES

Activation of GABAB receptors reverses spontaneous gating deficits in juvenile DBA/2J mice

Baclofen dose-dependently restored PPI deficit in DBA/2J mice, in a fashion similar to the antipsychotic clozapine, and this effect was reversed by pretreatment with the GABAB antagonist SCH50211.

Clozapine, GABAB, and the Treatment of Resistant Schizophrenia

The pharmacology of clozapine vis‐à‐vis schizophrenia is described, current evidence linking clozAPine to GABAergic neurotransmission is discussed, and alternative treatment methods that may lead to improved outcomes through the GABAergic system are highlighted.

The metabotropic GABA receptor: molecular insights and their functional consequences

Structural and functional modelling of the N-terminal domain of the GABAB R1 subunit has enabled the identification of residues whose substitution modulates agonist/antagonist binding affinities and the existence of as yet unidentified splice variants, additional receptor subtypes and alternative quaternary composition has not been ruled out.

The High-Affinity Binding Site for Tricyclic Antidepressants Resides in the Outer Vestibule of the Serotonin Transporter

The binding modes of tricyclic antidepressants are explored by homology modeling and docking studies and simultaneous binding of ibogaine and of carbamazepine is indicative of a second binding site in the inner vestibule, consistent with the pseudosymmetric fold of monoamine transporters.